TNNI3K and atrial fibrillation: In TNNI3K-p.His592Tyr variant carriers, we observed an increased burden of SVT (including atrioventricular-nodal reentry tachycardia, AF, atrial tachycardia, and possible junctional tachycardia) of 38% compared with an incidence of ~0.25% in the general population.24 The fact that we do not identify enrichment for SVT in the UK biobank data could be due to atrioventricular-nodal reentry tachycardia/SVT being specific to the p.His592Tyr variant.